Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 38481800)

  • 1. Impact of KRAS mutation on the tumor microenvironment in colorectal cancer.
    Zhou Y; Kuang Y; Wang C; Yu Y; Pan L; Hu X
    Int J Biol Sci; 2024; 20(5):1947-1964. PubMed ID: 38481800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of RAS mutations on the immune infiltrate of colorectal liver metastases: A preliminary study.
    Polidoro MA; Milana F; Soldani C; Franceschini B; Anselmo A; Colombo FS; Di Tommaso L; Cimino M; Carnevale S; Lleo A; Jaillon S; Torzilli G; Donadon M
    J Leukoc Biol; 2020 Aug; 108(2):715-721. PubMed ID: 32108374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy.
    Wang G; Wang JJ; Yin PH; Xu K; Wang YZ; Shi F; Gao J; Fu XL
    J Cell Physiol; 2019 May; 234(5):5601-5612. PubMed ID: 30341899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The current understanding on the impact of KRAS on colorectal cancer.
    Meng M; Zhong K; Jiang T; Liu Z; Kwan HY; Su T
    Biomed Pharmacother; 2021 Aug; 140():111717. PubMed ID: 34044280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status.
    Lee J; Jain A; Kim P; Lee T; Kuller A; Princen F; In-GuDo ; Kim SH; Park JO; Park YS; Singh S; Kim HC
    PLoS One; 2014; 9(8):e103551. PubMed ID: 25090459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant RAS and BRAF mutation in colorectal cancer - A report of 7 cases.
    Ates O; Yalcin S
    Indian J Cancer; 2019; 56(2):176-179. PubMed ID: 31062740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One Mutation to Rule Them All: Mutant KRAS Controls Tumor Intrinsic and Microenvironment Signaling.
    Müller S; Krishnamurty AT
    Cancer Res; 2024 Jan; 84(1):6-8. PubMed ID: 38016110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis.
    Jackstadt R; van Hooff SR; Leach JD; Cortes-Lavaud X; Lohuis JO; Ridgway RA; Wouters VM; Roper J; Kendall TJ; Roxburgh CS; Horgan PG; Nixon C; Nourse C; Gunzer M; Clark W; Hedley A; Yilmaz OH; Rashid M; Bailey P; Biankin AV; Campbell AD; Adams DJ; Barry ST; Steele CW; Medema JP; Sansom OJ
    Cancer Cell; 2019 Sep; 36(3):319-336.e7. PubMed ID: 31526760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colorectal cancer-derived exosomes and modulation KRAS signaling.
    Wan YH; Liu QS; Wan SS; Wang RW
    Clin Transl Oncol; 2022 Nov; 24(11):2074-2080. PubMed ID: 35789981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA‑337 inhibits colorectal cancer progression by directly targeting KRAS and suppressing the AKT and ERK pathways.
    Liu X; Wang Y; Zhao J
    Oncol Rep; 2017 Nov; 38(5):3187-3196. PubMed ID: 29048669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unveiling the role of KRAS in tumor immune microenvironment.
    Xu M; Zhao X; Wen T; Qu X
    Biomed Pharmacother; 2024 Feb; 171():116058. PubMed ID: 38171240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS as a Modulator of the Inflammatory Tumor Microenvironment: Therapeutic Implications.
    Pereira F; Ferreira A; Reis CA; Sousa MJ; Oliveira MJ; Preto A
    Cells; 2022 Jan; 11(3):. PubMed ID: 35159208
    [No Abstract]   [Full Text] [Related]  

  • 14. The potential of PIK3CA, KRAS, BRAF, and APC hotspot mutations as a non-invasive detection method for colorectal cancer.
    Alizadeh-Sedigh M; Mahmoodzadeh H; Fazeli MS; Haddadi-Aghdam M; Teimoori-Toolabi L
    Mol Cell Probes; 2022 Jun; 63():101807. PubMed ID: 35296442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long noncoding RNA SNHG14 accelerates cell proliferation, migration, invasion and suppresses apoptosis in colorectal cancer cells by targeting miR-944/KRAS axis through PI3K/AKT pathway.
    Pei Q; Liu GS; Li HP; Zhang Y; Xu XC; Gao H; Zhang W; Li T
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9871-9881. PubMed ID: 31799655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer.
    Bahrami A; Hassanian SM; ShahidSales S; Farjami Z; Hasanzadeh M; Anvari K; Aledavood A; Maftouh M; Ferns GA; Khazaei M; Avan A
    J Cell Physiol; 2018 Mar; 233(3):2058-2066. PubMed ID: 28262927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
    Wang Z; Kang B; Gao Q; Huang L; Di J; Fan Y; Yu J; Jiang B; Gao F; Wang D; Sun H; Gu Y; Li J; Su X
    Cancer Sci; 2021 Sep; 112(9):3895-3910. PubMed ID: 34185934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer.
    Zhu G; Pei L; Xia H; Tang Q; Bi F
    Mol Cancer; 2021 Nov; 20(1):143. PubMed ID: 34742312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAS mutation: site of disease and recurrence pattern in colorectal cancer.
    Bonnot PE; Passot G
    Chin Clin Oncol; 2019 Oct; 8(5):55. PubMed ID: 31597436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS inhibition in metastatic colorectal cancer: An update.
    Nusrat M; Yaeger R
    Curr Opin Pharmacol; 2023 Feb; 68():102343. PubMed ID: 36638742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.